In colorectal cancer, ESMO suggests that an optimal gene panel should detect KRAS, NRAS, BRAF, NTRK, and ERBB2 amplification, although NGS is still only considered for research purposes.9 This evidence concerns the gene KRAS and colorectal cancer.